Compounds > carboxyamido-triazole
Page last updated: 2024-09-02

carboxyamido-triazole and Cancer of Lung

carboxyamido-triazole has been researched along with Cancer of Lung in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, C; Chen, W; Guo, L; Ju, R; Li, J; Shi, J; Sun, F; Ye, C; Zhang, D; Zhu, L1
Ballman, KV; Bot, B; Buckner, JC; DeMatteo, RP; Hillman, SL; Mandrekar, SJ; Nelson, H; Perez, EA; Sargent, DJ1
Chiles, J; Kohn, EC; Moody, E; Moody, TW; Sieczkiewicz, GJ1
Adjei, AA; Bauman, MD; Bernath, AM; Fitch, TR; Graham, DL; Hauge, MD; Hillman, SL; Jett, JR; Johnson, EA; Kugler, JW; Mandrekar, SJ; Marks, RS; Moore, DF; Perez, EA; Soori, GS; Windschitl, HE; Wos, EJ1
Day, A; Felder, CC; Freer, R; Holmes, KA; Jacobs, W; Kohn, EC; Liotta, LA1

Trials

1 trial(s) available for carboxyamido-triazole and Cancer of Lung

ArticleYear
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).
    Lung cancer (Amsterdam, Netherlands), 2008, Volume: 60, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Placebos; Quality of Life; Triazoles

2008

Other Studies

4 other study(ies) available for carboxyamido-triazole and Cancer of Lung

ArticleYear
Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
    The Journal of pharmacology and experimental therapeutics, 2017, Volume: 362, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanog Homeobox Protein; Niacinamide; Phenylurea Compounds; Sorafenib; Triazoles; Xenograft Model Antitumor Assays

2017
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-20, Volume: 28, Issue:18

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Piperazines; Placebos; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Triazoles; Young Adult

2010
CAI inhibits the growth of small cell lung cancer cells.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 39, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Division; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured

2003
Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI.
    Cancer research, 1994, Feb-15, Volume: 54, Issue:4

    Topics: Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Arachidonic Acid; Calcium; Cell Division; CHO Cells; Cricetinae; Cricetulus; Humans; Lung Neoplasms; Signal Transduction; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured

1994